MetaCap

Celularity (CELU) vs NewcelX (NCEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NewcelX (NCEL) has outperformed Celularity (CELU) over the past year, losing 22.3% versus a loss of 73.5%. Over five years, CELU leads with a -99.3% price change compared with -99.7% for NCEL. Celularity is the larger company by market cap ($15.0 million vs $14.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CELU-73.54%NCEL-22.32%
+56%-12%-80%
Nov 21, 20251 yearNov 20, 2026
CELU-99.34%NCEL-99.68%
+84%-12%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CELU versus NCEL key metrics
MetricCELUNCEL
Share price$0.463$2.54
Market cap$15.02M$14.67M
1-day change-1.05%-5.58%
YTD return-58.29%+33.68%
1-year return-73.54%-22.32%
5-year return-99.31%-99.65%
P/E ratio (TTM)—4.88
EPS (TTM)$-1.69$0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$26.55M—
Revenue growth (YoY)-51.03%—
Net income (latest FY)$-91.72M$-8.30M
Gross margin24.39%—
Operating margin-230.92%—
Net margin-345.45%—
52-week high$2.55$5.12
52-week low$0.42$1.83
Distance from 52-week high-81.84%-50.39%
Analyst consensus—none
Avg. price target upside—+805.51%
Average volume3.95M13.34K
Shares outstanding32.45M5.78M
Employees1159
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NCEL has outperformed CELU by 51.2 percentage points over the past year.

About Celularity

CELU stock →

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.

Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees

About NewcelX

NCEL stock →

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

CELU vs NCEL FAQ

Which is bigger, Celularity or NewcelX?

Celularity (CELU) is larger, with a market capitalization of $15.02M compared with $14.67M for NewcelX (NCEL).

Which stock has performed better over the past year, CELU or NCEL?

NCEL returned -22.32% over the past 12 months, compared with -73.54% for CELU (price return, excluding dividends). Past performance does not predict future results.

Are Celularity and NewcelX in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons